EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer

A Phase 3, Multi-center, Randomized, Double-Blind, Placebo- Controlled Study to Assess the Efficacy and Safety of EN3285 for the Prevention or Delay to Onset of Severe Oral Mucositis in Patients With Head and Neck Cancer Receiving Chemoradiotherapy

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00574860

Enrollment

240

Registered

2007-12-17

Start date

2007-12-31

Completion date

2009-06-30

Last updated

2013-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer, Oral Mucositis

Keywords

Oral Mucositis, Chemoradiation therapy, Head and neck cancer

Brief summary

Randomized, double-blind, placebo-controlled study for the treatment of head and neck cancer(HNC), to assess the ability of EN3285 to prevent or delay the onset of severe oral mucositis(OM).

Detailed description

This randomized, double-blind, placebo-controlled study will be conducted in patients receiving chemoradiotherapy (ChemoRT) for the treatment of head and neck cancer(HNC), to assess the ability of EN3285 to prevent or delay the onset of severe oral mucositis(OM). The study includes a treatment period of up to 8 weeks, based on the patients' prescribed treatment plan, with a follow-up period of 12 months following completion of radiotherapy (RT).

Interventions

DRUGEN3285

Oral rinse

DRUGPlacebo

Oral rinse

OTHERStandard of care

This will be the therapy most commonly used the the institution treating the patient

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Significant Inclusion Criteria: * 18 years and older * newly diagnosed SCC of the oral cavity and/or oropharynx, and are intended for treatment with ChemoRT. * Have a clinical plan to receive a minimum of 60 Gy to the oral cavity and/or oropharynx * Chemotherapy: cisplatin * Have a WBC ≥3500 per cubic millimeter * Have a platelet count ≥100,000 per cubic millimeter * Have adequate renal function as determined by the principal investigator prior to enrollment * Are willing and able to undergo oral assessments * Have a Karnofsky Performance Status score ≥70 Significant

Exclusion criteria

* Have OM or other oral conditions at study entry * Plan to use Amifostine, Pilocarpine, Cevimeline or Bethanechol * Are using a pre-existing feeding tube for nutritional support at study entry * Plan to use any drug for the treatment or prevention of OM * Have had any prior radiotherapy to the head and neck * Have had prior chemotherapy within 6 months preceding enrollment * Plan to have concurrent chemotherapy, other than those regimens specified under inclusioncriteria * Have received other investigational drugs in the 30 days preceding initiation of study drug or during administration of study drug * Have medical conditions that require the use of chronic steroid therapy * Have the inability to undergo repeat treatments,

Design outcomes

Primary

Measure	Time frame
NCI v3 to measure severity of OM	At 50 Gy

Secondary

Measure	Time frame
WHO criteria for measuring severity of OM	At 50 Gy

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026